NCT04590664 is a Phase 1, PHASE2 clinical trial of Verteporfin in Glioblastoma, sponsored by Emory University.

Who is sponsoring NCT04590664?

NCT04590664 is sponsored by Emory University.

What drugs are being tested in NCT04590664?

Interventions in NCT04590664: Verteporfin.

What condition does NCT04590664 study?

NCT04590664 studies Glioblastoma, Recurrent Glioblastoma.

Is NCT04590664 still recruiting?

NCT04590664 is currently recruiting now. Last updated 25 February 2025.

Last reviewed 2025-02-25 · How we verify

NCT04590664

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

Recruiting now Phase 1, PHASE2 Last updated 25 February 2025

What this trial tests

Phase 1, PHASE2 trial testing Verteporfin in Glioblastoma in 24 participants. Currently enrolling.

Timeline

15 January 2021

Primary endpoint
15 August 2025

15 August 2025

Quick facts

Lead sponsor	Emory University
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	15 January 2021
Primary completion	15 August 2025
Estimated completion	15 August 2025
Sites	1 location across United States

Drugs / interventions tested

Verteporfin (VERTEPORFIN) — full drug profile →

Conditions studied

Glioblastoma — all drugs for Glioblastoma →
Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →

Sponsor

Emory University

Who can join

18 and older, any sex, with Glioblastoma or Recurrent Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent). Visudyne is FDA approved in combination with light to treat eye diseases. In this study we use Visudyne by itself like chemotherapy to kill tumor cells which may be sensitive to verteporfin.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy.
Jiang Y, Zhang H, Wang J, Liu Y, et al · · 2022 · cited 342× · PMID 35331296 · DOI 10.1186/s13045-022-01252-0
Engineering photodynamics for treatment, priming and imaging.
Obaid G, Celli JP, Broekgaarden M, Bulin AL, et al · · 2024 · cited 88× · PMID 39927170 · DOI 10.1038/s44222-024-00196-z
Signaling pathways in liver cancer: pathogenesis and targeted therapy.
Xue Y, Ruan Y, Wang Y, Xiao P, et al · · 2024 · cited 43× · PMID 38816668 · DOI 10.1186/s43556-024-00184-0
Matrix stiffness affects tumor-associated macrophage functional polarization and its potential in tumor therapy.
Xiong J, Xiao R, Zhao J, Zhao Q, et al · · 2024 · cited 39× · PMID 38246995 · DOI 10.1186/s12967-023-04810-3
TEAD4 as an Oncogene and a Mitochondrial Modulator.
Hsu SC, Lin CY, Lin YY, Collins CC, et al · · 2022 · cited 29× · PMID 35602596 · DOI 10.3389/fcell.2022.890419
Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery.
Quinlan JA, Inglut CT, Srivastava P, Rahman I, et al · · 2024 · cited 26× · PMID 38445882 · DOI 10.1002/advs.202302872
Multi-Functional Regulation by YAP/TAZ Signaling Networks in Tumor Progression and Metastasis.
Thrash HL, Pendergast AM. · · 2023 · cited 25× · PMID 37835395 · DOI 10.3390/cancers15194701
Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP/TAZ Inhibition.
Alhousami T, Diny M, Ali F, Shin J, et al · · 2022 · cited 25× · PMID 35105672 · DOI 10.1158/1541-7786.mcr-21-0310

Verify or expand the search:

Other trials of Verteporfin

Trials testing the same drug.

NCT06381154 — Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or · Phase 2 · recruiting
NCT06306638 — Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Centr · Phase 1, PHASE2 · recruiting
NCT05589974 — Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy · recruiting
NCT03033225 — Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced · Phase 2 · completed
NCT03067051 — Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System · Phase 1, PHASE2 · recruiting

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Emory University trials

Trials by the same sponsor.

NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04590664 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 25 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04590664.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing